News and Trends 22 Jun 2023 Alchemab Therapeutics unveils Alzheimer’s candidate Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium… June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 31 Jan 2017 Biologicals on the Brain: Biotech in Neurodegenerative Disease …Less than a month after Lilly’s announcement, Biogen released positive data on its Phase 1b trial of aducanumab, an antibody candidate now in Phase III trials, reviving hopes for the… January 31, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2025 Ten first-in-class drugs on track for FDA approval in 2025 …two main components: Monoclonal antibody (telisotuzumab): This antibody specifically binds to the c-Met protein on the surface of cancer cells. Cytotoxic agent (monomethyl auristatin E – MMAE): Once the antibody… January 16, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Swiss Antibodies Recruited by the Developer of BMS’ Cancer Blockbuster …sales, in exchange for the development of an immuno-oncology antibody candidate. For Numab, this deal with an oncology veteran certainly reinforces the potential of its antibody technology. The Japanese company… March 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 23 Nov 2022 What recent mixed clinical results can teach about Alzheimer’s disease …Abeta. Varoglutamstat also blocks the pathology earlier in the process than leading antibody candidates, and can be taken orally — a more convenient drug delivery than injecting or infusing antibody… November 23, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Aug 2025 10 biotech companies you should know about in Spain …of antibody-drug conjugates (ADCs) that “exploit the molecular underpinnings” of advanced cancer. The company’s lead candidate is called ONA-255, which is a first-in-class ADC that is being developed to treat… August 19, 2025 - 16 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma …of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization. The CDMO will produce sufficient amounts of drug candidate to complete… August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 May 2025 Finland: Pushing biotech forward in the land of a thousand lakes …the country’s landscape. Here are nine biotech companies pushing the industry forward in Finland. Table of contents Aplagon Foundation: 2009 Lead candidate: APAC Recent news: Secured a €7 million funding… May 23, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Mar 2024 Eight CAR-T cell therapy companies you should know about …offering, American company CARGO Therapeutics has begun a phase 2 trial for its lead CAR-T cell therapy candidate CRG-022. The candidate targets CD22, a B-cell specific antigen that is expressed… March 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? …advance the development of this candidate. This comes after the clinical evaluation of several modified-release once-daily formulations of danuglipron resulted in “encouraging pharmacokinetic data” for several candidates, with one showing… July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Feb 2025 T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments …lurking? At present, there are a number of T cell engagers in the clinic. California-based Janux Therapeutics has two candidates in phase 1 trials. Its lead candidate JANX007 is designed… February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Oct 2025 Six companies leading the mRNA revolution in biotechnology …mRNA pipeline centered around treating cancer, infectious diseases, and rare diseases. Two of its infectious disease candidates are in phase 1 trials, namely RV-1730 and RV-1770. The candidate RV-1730 is… October 7, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email